DeepMed Research

University Health Network

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1999-01-01

Employees: 10K

Market Cap: -

Website: http://www.uhn.ca

Clinical Trials

Survey of the Facial Bacteriome

Completed

Conditions: Microbial Colonization
Understanding Skin Health and the Microbiome

Interventions: Other: fluorescence imaging with 405nm light

First Posted Date: 2019-11-29

Last Posted Date: 2021-03-29

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 30

Registration Number: NCT04180748

Locations: 🇨🇦
Princess Margaret Cancer Research Tower, Toronto, Ontario, Canada

Acute Olanzapine and Lipid Response

Phase 2

Conditions: Healthy

Interventions: Drug: Olanzapine 10 milligram
Drug: Placebo oral tablet
Drug: Bromocriptine 5 milligram

First Posted Date: 2019-11-29

Last Posted Date: 2019-12-03

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 15

Registration Number: NCT04181385

Locations: 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada

Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer

Phase 2

Not yet recruiting

Conditions: Prostate Cancer

Interventions: Radiation: Radiation Therapy
Drug: Darolutamide
Drug: Degarelix

First Posted Date: 2019-11-25

Last Posted Date: 2024-01-24

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 208

Registration Number: NCT04176081

Locations: 🇨🇦
UHN Princess Margaret Hospital, Toronto, Ontario, Canada

Talazoparib and Thoracic RT for ES-SCLC

Phase 1

Recruiting

Conditions: Lung Cancer
Small-Cell Lung Cancer

Interventions: Other: Talazoparib in Combination with Low Dose Radiotherapy (RT)

First Posted Date: 2019-11-20

Last Posted Date: 2025-02-20

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 24

Registration Number: NCT04170946

Locations: 🇨🇦
Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada

Perfexion Registration Using CBCT

Completed

Conditions: Brain Metastases

First Posted Date: 2019-11-20

Last Posted Date: 2023-01-26

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 1250

Registration Number: NCT04170777

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Brexpiprazole
Drug: Escitalopram

First Posted Date: 2019-11-14

Last Posted Date: 2023-03-02

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 1

Registration Number: NCT04162522

Locations: 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦
Queen's University, Kingston, Ontario, Canada

and more 3 locations

Fluorescence Image-Guided Healing Trial

Phase 4

Conditions: Diabetic Foot Ulcer

First Posted Date: 2019-11-14

Last Posted Date: 2020-11-03

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 294

Registration Number: NCT04163055

A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer

Phase 2

Recruiting

Conditions: Endometrial Carcinoma
P53 Mutation
Serous Carcinoma

Interventions: Radiation: External Beam Radiation
Radiation: Vaginal high-dose rate brachytherapy
Other: Observation - no drugs
Drug: Niraparib

First Posted Date: 2019-11-12

Last Posted Date: 2024-01-31

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 267

Registration Number: NCT04159155

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Recruiting

Conditions: Malignancies Multiple
Receptor Tyrosine Kinase Gene Mutation
Ras (Kras or Nras) Gene Mutation
Cancer
Molecular Sequence Variation
Cancer, Therapy-Related
Genetic Alteration
Malignant Solid Tumor
Gene Fusion
RTK Family Gene Mutation

Interventions: Drug: Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.
Other: Patient-reported outcomes (PROs)

First Posted Date: 2019-11-05

Last Posted Date: 2024-05-31

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 1000

Registration Number: NCT04151342

Locations: 🇨🇦
William Osler Health System - Brampton Civic Hospital, Brampton, Ontario, Canada
🇨🇦
Lawson Health Research Institute - London Health Sciences Centre, London, Ontario, Canada
🇨🇦
CancerCare Manitoba/University of Manitoba, Winnipeg, Manitoba, Canada

and more 24 locations

Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy

Not Applicable

Suspended

Conditions: Surgery
BRCA1 Mutation
Breast Cancer
Surgery--Complications
Breast Diseases
Genetic Predisposition to Disease
BRCA2 Mutation

Interventions: Procedure: Robotic Nipple-Sparing Mastectomy (RNSM)

First Posted Date: 2019-11-05

Last Posted Date: 2025-01-31

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 30

Registration Number: NCT04151368

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy